May 31, 2019 - Biogen (BIIB) announces new interim results from phase III EVOLVE-MS-1 study, which showed that the diroximel fumarate was generally well tolerated in people with relapsing MS.
May 31, 2019 - Novartis' (NVS) investigational, once-daily, fixed dose combination asthma candidate, containing indacaterol acetate and mometasone furoate, meets goals.
May 30, 2019 - Novartis' new gene therapy, Zolgensma, may be the most expensive drug ever, but there's much more to the story.
May 27, 2019 - Novartis (NVS) obtains FDA approvals for a breast cancer drug and a gene therapy for pediatric patients.
May 27, 2019 - Incyte (INCY) obtains FDA approval for a third indication of lead drug, Jakafi, for the treatment of GVHD.
May 26, 2019 - Getting end payers on board with a seven-figure price for Zolgensma won't be easy.
May 24, 2019 - A $2.1 million price tag could make Zolgensma a blockbuster medicine for these companies.
May 23, 2019 - Novartis (NVS) reports encouraging data on combination asthma drug. The company also highlights its growth plans at its annual meet.
May 20, 2019 - Adverum's (ADVM) stock gains as the FDA lifts the clinical hold on the second cohort of an initial stage study on lead candidate.
May 17, 2019 - KBC Group NV (OTCPK:KBCSF) Q1 2019 Results Conference Call May 16, 2019 03:30 AM ET Company Participants Kurt De Baenst - Investor Relations Johan Thijs - CEO Rik Scheerlinck - CFO Conference Call Par